Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Interest Income

Income earned on cash, deposits, and investments held by the company.

Autolus Therapeutics plcNASDAQ: AUTL

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $2.47M fell 59.8% year over year, behind the -29.9% change in trailing-twelve-month interest income. Sequentially, it fell 23.4% from the prior quarter. Over 3 fiscal years it compounded at +123.3% a year.

Context

  • Interest income amounted to 25.2% of revenue in FY2025, down 294.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -59.8% toward the trailing-twelve-month pace of -29.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.47M-23.4% QoQ
Last fiscal yearDec 2025
$19.02M-41.2% YoY
LTMMar 2026
$22.14M-29.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.8%——
1 year-41.2%——
3-year CAGR+123.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
19.02M USD
Year-over-year change
-41.2%
4-year CAGR
+191.9%

Interest Income vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 interest income of $22.14M is the 2nd highest of the 10 companies compared; the peer median is $8.47M.
  • Its year-over-year change of -29.9% is the 2nd highest of 9, against a peer median of -42.4%.
  • Interest income amounts to 23.9% of revenue for AUTL, versus a peer median of 8.7%.
AUTL Competitors Peer median
Interest Income for AUTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M -48.6%+69.9%1.7%
AUTLAutolus Therapeutics plcLTM Mar 2026$22.14M -29.9%+123.3%23.9%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M -14.3%+61.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$11.41M -45.9%+22.9%36812.9%
FATEFate Therapeutics, Inc.LTM Mar 2026$9.58M -41.8%+23.7%151.7%
CLLSCellectis S.A.LTM Mar 2026$8.47M -30.9%+103.9%12.4%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$6.94M -43.0%+34.9%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$3.92M -39.0%+6.9%8.7%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$501K -71.2%-39.3%2.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 —+20.3%0.0%
Peer median (excluding AUTL) $8.47M-42.4%+23.7%8.7%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.